Watchman FLX Delivers Big Stroke‑Prevention Win for Boston Scientific

Boston Scientific (NYSE: BSX) reported new CHAMPION‑AF data at ACC.26 showing its WATCHMAN FLX left atrial appendage closure device met all primary and secondary safety and efficacy endpoints versus leading NOAC blood thinners in patients with non‑valvular atrial fibrillation (NVAF). The late‑breaking results, simultaneously published in The New England Journal of Medicine, position WATCHMAN FLX as a potential first‑line alternative to long‑term anticoagulation for a broad AF population.

Stroke protection with less bleeding

In CHAMPION‑AF, WATCHMAN FLX achieved similar protection from stroke, cardiovascular or unexplained death, and systemic embolism compared with NOACs while significantly cutting non‑procedural bleeding. The device delivered a 45% relative reduction in non‑procedural major and clinically relevant non‑major bleeding (10.9% vs. 19.0%), and a 34% reduction when procedural bleeding was included (12.8% vs. 19.0%).

Net clinical benefit vs. NOACs

Beyond headline safety and efficacy, a combined endpoint of cardiovascular death, stroke, systemic embolism, and non‑procedural bleeding favored WATCHMAN FLX, with a 15.1% event rate versus 21.8% for NOACs, achieving statistical superiority. Investigators highlighted that the device was also non‑inferior to NOACs for major bleeding at 36 months, reinforcing a net clinical benefit in real‑world decision‑making.

First‑line potential in a large AF market

AF affects an estimated 59 million people worldwide, and many eligible patients either cannot tolerate or do not consistently take oral anticoagulants, leaving a large undertreated segment. Boston Scientific sees these data as the basis for expanding WATCHMAN FLX indications and elevating it to a frontline stroke‑risk reduction option, which could structurally increase the addressable market for its LAAC franchise.

Strategic implications for BSX investors

For Boston Scientific shareholders, CHAMPION‑AF helps solidify WATCHMAN FLX as a differentiated, guideline‑shaping platform rather than a niche alternative for high‑bleeding‑risk patients. Strong, long‑term data that support broader use could translate into durable growth in BSX’s higher‑margin structural heart portfolio and reinforce the company’s premium multiple in cardiovascular medtech.